8-K
filed May 4, 2026, 7:59 PM ET
ticker GILD
CIK 0000882095
other material
confidence high
sentiment neutral
materiality 0.15
Gilead shareholders elect all nine directors, approve equity plan increase, reject three proposals
GILEAD SCIENCES, INC.
- All nine director nominees elected; Daniel O'Day received 980.6M votes for, 50.2M against.
- Ernst & Young ratified as auditor for FY 2026: 1,046.4M for, 82.8M against, 1.0M abstain.
- Say-on-pay approved with 954.3M for (92.6% of votes cast excluding broker non-votes).
- Amended 2022 Equity Incentive Plan approved, adding 47.75M new shares to the pool.
- Shareholder proposals on independent chair, patent exclusivity, and ESG metrics all defeated by wide margins.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GILEAD SCIENCES, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-04-30 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-04-30
Exact text from the filing
The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following votes: Votes For 1,046,350,569 Votes Against 82,831,295 Abstentions 998,602
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GILEAD SCIENCES, INC. shareholders approved Election of nine directors at the 2026-04-30 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-04-30
Exact text from the filing
Name Votes For Votes Against Abstentions Broker Non-Votes Jacqueline K. Barton, Ph.D. 1,013,176,696 21,056,724 938,657 95,008,389 Jeffrey A. Bluestone, Ph.D. 1,017,337,149 16,873,041 961,887 95,008,389 Sandra J. Horning, M.D. 1,002,426,858 31,078,619 1,666,600 95,008,389 Kelly A. Kramer 995,947,854 38,240,224 983,999 95,008,389 Ted W. Love, M.D. 1,016,607,688 17,592,385 972,004 95,008,389 Harish Manwani 995,710,468 38,469,820 991,789 95,008,389 Daniel P. O’Day 980,597,212 50,179,985 4,394,880 95,008,389 Javier J. Rodriguez 1,019,197,783 15,002,200 972,094 95,008,389 Anthony Welters 992,619,897 40,842,646 1,709,534 95,008,389
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access at the 2026-04-30 meeting.
- Outcome
- failed
- Meeting
- 2026-04-30
Exact text from the filing
The Company’s stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes: Votes For 134,042,210 Votes Against 886,986,584 Abstentions 14,143,283 Broker Non-Votes 95,008,389
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GILEAD SCIENCES, INC. shareholders approved Amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan at the 2026-04-30 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-04-30
Exact text from the filing
The Company’s stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes: Vote For 970,290,586 Vote Against 62,501,433 Abstentions 2,380,058 Broker Non-Votes 95,008,389
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting an independent Board Chair policy at the 2026-04-30 meeting.
- Outcome
- failed
- Meeting
- 2026-04-30
Exact text from the filing
The Company’s stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes: Votes For 280,044,780 Votes Against 752,716,225 Abstentions 2,411,072 Broker Non-Votes 95,008,389
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics at the 2026-04-30 meeting.
- Outcome
- failed
- Meeting
- 2026-04-30
Exact text from the filing
The Company’s stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes: Votes For 7,262,421 Votes Against 1,022,330,186 Abstentions 5,579,470 Broker Non-Votes 95,008,389
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GILEAD SCIENCES, INC. shareholders approved Advisory approval of compensation of Named Executive Officers at the 2026-04-30 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-04-30
Exact text from the filing
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes: Votes For 954,325,805 Votes Against 77,503,947 Abstentions 3,342,325 Broker Non-Votes 95,008,389
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.